Chronic hepatitis C: current status of the issue, epidemiological trends, and clinical outcomes in the era of directacting antiviral therapy (a systematic review and meta-analysis)
Abstract
The paper aims to present a comprehensive analysis of the global burden of chronic hepatitis C (CHC) and assess the evolution of epidemiological indicators, the efficacy and safety of modern direct-acting antiviral (DAA) regimens, and long-term clinical outcomes over the period 2021–2026. Materials and Methods. A systematic literature review was conducted in accordance with the PRISMA 2020 guidelines. The search was performed in the PubMed, Embase, Scopus, Cochrane Library, and Google Scholar databases for the period from January 1, 2021 to March 1, 2026. Reports from the World Health Organization (WHO), data from the Polaris Observatory, and the EASL and AASLD registries were additionally included. Of the 2,486 records initially identified, 147 studies (population-based cohorts, randomized controlled trials (RCTs), systematic reviews, and meta-analyses) were included in the final analysis after screening. Random-effects models were used for quantitative synthesis, and heterogeneity was assessed using I². Results. The global prevalence of hepatitis C virus (HCV) infection declined from 1.0% (2015) to 0.7% (2024); however, the absolute number of infected individuals remains at 50-56 million.
The highest concentration of infection persists in Eastern Europe, Central Asia, and sub-Saharan Africa. Sustained virologic response at 12 weeks after the end of therapy (SVR12) with pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) exceeds 96% in the general…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
- A meta‐analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale
- Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021
- Exercise interventions in Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials
- Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis
- Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.